LAG3 and melanoma: In conclusion, LAG3 inhibition for treating metastatic or unresectable melanoma has a reduced efficacy in subjects with T2D, possibly due to a low expression of LAG3. Although current evidence cannot prove the causative role of glycemia on reduced efficacy of LAG3 inhibition, data suggest that glycemia should be monitored and maintained within control levels in these patients.